LOUISVILLE, Kentucky — Compared with placebo, treatment with peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia) significantly improved the amount of peanut protein that could be tolerated by peanut-allergic children between 1-3 years of age after 12 months of treatment with the oral immunotherapy, according to results of a randomized clinical trial.
The phase 3 POSEIDON study also showed that the oral immunotherapy featured a favorable safety profile in this young patient population.
Findings of the trial were presented here by George du Toit, MB BCh, at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting 2022.
In an interview with Medscape Medical News, du Toit, a professor of pediatric allergy at Evelina London Children's Hospital in the UK, explained that at present the United States has no licensed treatment for children with peanut allergy who are younger than 4 years of age. Avoidance currently represents the only effective option for preventing allergic reactions in these patients.
Peanut allergen powder-dnfp is an oral immunotherapy that is currently approved by the US Food and Drug Administration (FDA) for the mitigation of allergic reactions associated with accidental exposure to peanuts in patients aged 4-17 years with a confirmed diagnosis of peanut allergy.
